SAN DIEGO--(BUSINESS WIRE)--Calimmune, Inc. today announced that encouraging results from a first group of participants indicates the company is ready to begin treating a second cohort in a clinical trial involving the use of Cal-1, an innovative gene-based stem cell therapy to help protect individuals infected with HIV from progressing to AIDS.
Help employers find you! Check out all the jobs and post your resume.
